ESR1 and breast cancer: Furthermore, treatment with gefitinib, a tyrosine kinase inhibitor, resulted in the re-expression of ERα in ERα-negative breast cancer cell lines like SUM 190 and SUM-229PE by inhibiting the MAPK pathway [12,55].